Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... September 10, 2022 A Robust, Durable Activity of Atezolizumab Observed in a Diverse Cohort... September 21, 2023 ESMO Announces Results of 2025 Elections June 14, 2025 Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital September 16, 2021 Load more HOT NEWS How the National Cancer Act Has Made a Difference in Cancer... Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year...
